Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor II and Factor V with Risk of Inhibitor Development in Patients with Severe Hemophilia A

Author(s): Shahrzad Soori, Ghazaleh Dadashizadeh, Akbar Dorgalaleh, Shadi Tabibian, Mohammad R. Keramati, Shaban Alizadeh, Maryam S. Hosseini, Farhad Zaker*, Mahmood Shams.

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Volume 19 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: About one-fourth of patients with hemophilia A (HA) develop alloantibodies against factor (F) VIII, as the main treatment challenge. Here, we assessed the relationship between interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α), FII and FV polymorphisms and risk of inhibitor formation in patients with severe HA.

Methods: We divided 39 patients with severe HA in two groups of case (n: 19) and control (n: 20). Genotyping was performed by multiplex amplification tetra arms refractory mutation systempolymerase chain reaction (ARMS-PCR) and PCR-restriction fragment-length polymorphism (PCR-RFLP).

Results: TNFα rs1800629 G>A polymorphism decreased the risk of inhibitor development in codominant and dominant inheritance pattern. Moreover, TNFα rs1800629 A allele, decrease the risk of inhibitor formation, while IL10 rs1800896 A>G, FV rs6025 G>A, and FII rs1799963 G>A polymorphisms were not associated with risk of inhibitor development.

Conclusion: It seems that TNFα rs1800629 G>A polymorphism decreased the risk of inhibitor formation in Iranian patients with HA.

Keywords: Hemophilia A, IL10, TNF a, inhibitor, polymorphism, factor V, factor II.

[1]
Dorgalaleh, A.; Dadashizadeh, G.; Bamedi, T. Hemophilia in Iran. Hematology, 2016, 21(5), 300-310.
[2]
Chaves, D.; Belisário, A.; Castro, G.; Santoro, M.; Rodrigues, C. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A. Int. J. Immunogenet., 2010, 37(2), 79-82.
[3]
Gouw, S.C.; Van Der Bom, J.G.; Ljung, R.; Escuriola, C.; Cid, A.R.; Claeyssens-Donadel, S.; van Geet, C.; Kenet, G.; Mäkipernaa, A.; Molinari, A.C.; Muntean, W.; Kobelt, R. for the PedNet and RODIN Study Group.. Factor VIII products and inhibitor development in severe hemophilia A. N. Engl. J. Med., 2013, 368(3), 231-239.
[4]
Rahimi, Z.; Vaisi-Raygani, A.; Mozafari, H.; Kharrazi, H.; Rezaei, M.; Nagel, R.L. Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran. J. Thromb. Thrombolysis, 2008, 25(3), 280-283.
[5]
Astermark, J.; Oldenburg, J.; Carlson, J.; Pavlova, A.; Kavakli, K.; Berntorp, E.; Lefvert , AK. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood, 2006, 108(12), 3739-3745.
[6]
Kenet, G.; Bidlingmaier, C.; Bogdanova, N.; Ettingshausen, C.E.; Goldenberg, N.; Gutsche, S.; Halimeh, S.; Holzhauer, S.; Kurnik, K.; Gutsche ; Halimeh, S.; Holzhauer, S.; Kurnik, K.; Limperger, V.; Junker, R., S.; Limperger, V.; Junker, R. Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A-an Israeli-German multicenter database study. Thromb. Res., 2014, 133(4), 544-549.
[7]
Coppola, A.; Santoro, C.; Tagliaferri, A.; Franchini, M.; Di Minno, G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia, 2010, 16(s1), 13-19.
[8]
Witmer, C.; Young, G. Factor VIII inhibitors in hemophilia A: Rationale and latest evidence. Ther. Adv. Hematol., 2013, 4(1), 59-72.
[9]
Miller, S.; Dykes, D.; Polesky, H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res., 1988, 16(3), 1215.
[10]
Cnossen , D.P.; , C.R.; , S.; van Heerde, W.L.; Hermans, C.; Holmström, M., M.H.; Dors, N.; Escuriola-Ettingshausen, C.; Hamulyak, K.; Hart, D.P.; Hay, C.R.; Haya, S.; van Heerde, W.L.; Hermans, C.; Holmström, M.; Jimenez-Yuste, V. Keenan, R.D.; Klamroth, R.; Laros-van Gorkom, B.A.; Leebeek, F.W.; Liesner, R.; Mäkipernaa, A.; Male, C.; Mauser-Bunschoten, E.; Mazzucconi, M.G.; McRae, S.; Meijer, K.; Mitchell, M.; Morfini, M.; Nijziel, M.; Oldenburg, J.; Peerlinck, K.; Petrini, P.; Platokouki, H.; Reitter-Pfoertner, S.E.; Santagostino, E.; Schinco, P.; Smiers, F.J.; Siegmund, B.; Tagliaferri, A.; Yee, T.T.; Kamphuisen, P.W.; van der Bom, J.G.; Fijnvandraat, K.; INSIGHT Study Group.. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood, 2013, 122(11), 1954-1962.
[11]
Oldenburg, J.; El‐Maarri, O.; Schwaab, R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia, 2002, 8(s2), 23-29.
[12]
Marchione, V.; Zuccoli, J.; Abelleyro, M.; Radic, C.; Neme, D.; Candela, M.; de Tezanos Pinto, M.; De Brasi, C.D.; Rossetti, , L.C. A prevalent CTLA4 missense variant significantly associates with inhibitor development in Argentine patients with severe haemophilia A. Haemophilia, 2017, 23(2), e166-e169.
[13]
Bafunno, V.; Santacroce, R.; Chetta, M.; D’ANDREA, G.; Pisanelli, D.; Sessa, F.; Trotta, T.; Tagariello, G.; Peyvandi, F.; Margaglione, M. Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A. Haemophilia, 2010, 16(3), 469-473.
[14]
Schwoob, R.; Brockmonn, H.; Meyer, C.; Seehofer, J.; Kirchgesser, M.; Hoock, A.; Olek, K.; Tuddenham, E.G.; Oldenburg, J. Hoemophilid A: Mutation Type Determines Risk of Inhibitor Formation. Thromb. Haemost., 1995, 74(6), 1402-1406.
[15]
Ferrante, A.; Mosher, B.; Hoffman, M. Immune-related gene polymorphisms as risk factors for the development of Factor VIII inhibitors in hemophilia A patients: A sibling-pair association analysis (HUM1P. 257). Am. Assoc. Immnol., 2015, 194(1s), 52-56.
[16]
Pavlova, A.; Delev, D.; Lacroix‐Desmazes, S.; Schwaab, R.; Mende, M.; Fimmers, R.; Astermark, J.; Oldenburg, J. Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia A. J. Thromb. Haemost., 2009, 7(12), 2006-2015.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2019
Page: [228 - 232]
Pages: 5
DOI: 10.2174/1871529X19666190206152315
Price: $58

Article Metrics

PDF: 24
HTML: 2

Special-new-year-discount